2022-500398-15-00
Completed
Phase 1
A trial to learn if REGN7999 is safe and well tolerated, and how it works in the body of healthy participants.
Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.1 site in 1 country64 target enrollmentStarted: October 3, 2022Last updated:
Overview
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Regeneron Pharmaceuticals Inc., Regeneron Pharmaceuticals Inc.
- Enrollment
- 64
- Locations
- 1
Overview
Brief Summary
No summary available.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Investigators
Medical Affairs
Scientific
Regeneron Pharmaceuticals Inc.
Study Sites (1)
Loading locations...
Similar Trials
Not yet recruiting
Phase 1
A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin2025-521921-34-00Genentech Inc.32
Recruiting
Phase 1
A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control2024-519277-18-00F. Hoffmann-La Roche AG40
Recruiting
Phase 2
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)2023-508603-21-00Regeneron Pharmaceuticals Inc.93
Not yet recruiting
Phase 1
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.2023-505185-28-00F. Hoffmann-La Roche AG52
Completed
Phase 1
A Trial to Determine the Safety of CC-93269, an Antibody, in People who have Multiple Myeloma That Has Returned After a Period of Treatment And is not Responsive After Treatment.2023-506564-14-00Celgene International II S.a.r.l.112